Oregovomab

DB04964InvestigationalProtein Based Therapies

Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.

Mechanism: Oregovomab targets the circulating tumour-associated antigen CA 125, which is shed from the surface of human ovarian cancer cells; the antibodies induce broad cellular and humoral immune responses against CA 125 via complex formation. Unlike free CA 125, CA 125-oregovomab complexes can prime dendritic cells, leading to downstream activation of T cells.
Curator reviewed
Primary indication: Investigated for use/treatment in ovarian cancer.Curator reviewed
Also known as: Monoclonal antibody B43.13 · Oregovamab
Code names: B 4313 · MAb-B 4313

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

420Drug interactionsStructured to mechanism, not free text

16Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Oregovomab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.